Preview

Russian Journal of Cardiology

Advanced search

Smoke cessation in cardiovascular pathology from the perspective of evidence-based medicine

https://doi.org/10.15829/1560-4071-2019-2-86-91

Abstract

The effectiveness of smoking cessation methods has been studied in various studies. However, little is known about the peculiarities of treatment of nicotine dependence in patients with cardiovascular diseases. In the presented review, according to the literature, the prevalence and characteristics of smoking, the duration of abstinence from smoking in patients with cardiovascular diseases with different methods of quitting tobacco use are described.

It is shown that smoking cessation not only shows long-term positive effects, but almost immediately the supply of cells with oxygen increases, platelet aggregation, fibrinogen synthesis decreases. Carrying out treatment for nicotine addiction, especially when combined with behavioral support, significantly increases the effectiveness of quitting smoking. With the cardiovascular pathology, the efficacy and safety of varenicline has been proven.

About the Authors

O. A. Sukhovskaya
Saint-Petersburg State Research Institute of Phthisiopulmonology; First Pavlov State Medical University of St. Petersburg
Russian Federation

Competing Interests:

nothing to declare



N. V. Kulikov
Saint-Petersburg University
Russian Federation

Competing Interests:

nothing to declare



References

1. Obrezan AG, Kulikov NV. Evaluation of the behavioral risk factors for coronary heart disease (review). Medicinskij al'yans. 2018;1:84-8. (In Russ.)

2. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease. A Report of the Surgeon General. Centers for Disease Control and Prevention (US); National Center for Chronic Disease Prevention and Health Promotion (US); Office on Smoking and Health (US). Atlanta (GA): Centers for Disease Control and Prevention (US); 2010. ISBN-13: 978-0-16-084078-4. https://www.ncbi.nlm.nih.gov/books/NBK53017/.

3. The Health Consequences of Smoking — 50 Years of Progress. A Report of the Surgeon General. National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. Atlanta (GA): Centers for Disease Control and Prevention (US); 2014. https://www.ncbi.nlm.nih.gov/books/NBK179276/.

4. Schauer GL, Malarcher AM, Zhang L, et al. Prevalence and correlates of quitline awareness and utilization in the United States: an update from the 2009-2010 National Adult Tobacco Survey. Nicotine & Tobacco Research 2013, Nicotine Tob Res. 2014 May;16(5):544-53. doi:10.1093/ntr/ntt181.

5. Panov AV, Abesadze IT, Alugishvili MZ, et al. Register of patients who underwent coronary artery bypass surgery for ischemic heart disease with a stable course (RIKOSHET). Arterial'naya gipertenziya. 2014;20(6):568-77 (In Russ.)

6. Lariscy JT. Smoking-attributable mortality by cause of death in the United States: An indirect approach. SSM Popul Health. 2019; 11(7): 100349. doi:10.1016/j.ssmph.2019.100349.

7. Titova ON, Kulikov VD, Sukhovskaya OA. Passive smoking and respiratory diseases. Medicinskij al'yans. 2016;(3):73-7 (In Russ.)

8. 8 Hunter KA, Garlick PJ, Broom I, et al. Effects of smoking and abstention from smoking on fibrinogen synthesis in humans. Clin Sci (Lond). 2001 Apr;100(4):459-65.

9. Kawada T. Relationships between the smoking status and plasma fibrinogen, white blood cell count and serum C-reactive protein in Japanese workers.Diabetes Metab Syndr. 2015 Jul-Sep;9(3):180-2. doi:10.1016/j.dsx.2015.02.010.

10. Sukhovskaya OA, Obuhovskaya AS, Kulikov NV. Carbon monoxide levels in exhaled air as an indicator of adolescent smoking Akademicheskij zhurnal Zapadnoj Sibiri. 2009;(6):46. (In Russ.)

11. Chow CK, Jolly S, Rao-Melacini P. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation. 2010;121:750-8. doi:10.1161/circulationaha.109.891523.

12. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2004;1:CD003041.

13. van Domburg RT, op Reimer WS, Hoeks SE. Three life-years gained from smoking cessation after coronary artery bypass surgery: a 30-year follow-up study. Am Heart J. 2008;56:473-6. doi:10.1016/j.ahj.2008.04.007.

14. Sakharova GM, Antonov NS, Salagai OO. A global poll of adult population about tobacco consumption in the Russian Federation: the GATS the GATS 2009 And 2016. Narcologia. 2017; 16(7):8-12. (In Russ.)

15. Butler K, Rusted J, Gard P, Jackson A. Performance monitoring in nicotine dependence: Considering integration of recent reinforcement history. Pharmacol Biochem Behav. 2017 May;156:63-70. doi:10.1016/j.pbb.2017.04.004.

16. Filippova OV. Partial nicotinic receptor agonists in the treatment of tobacco dependence. Medicinskij al'yans. 2015;4:88-97. (In Russ.)

17. 17 Danielson K, Putt F, Truman P, Kivell BM. The effects of nicotine and tobacco particulate matter on dopamine uptake in the rat brain synapse. 2014 Feb;68(2):45-60. doi:10.1002/syn.21715.

18. Doering PL, Li RM. Substance-related disorders II: Alcohol, nicotine, and caffeine. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: A Pathophysiologic Approach. 9th ed. The McGraw-Hill Companies; New York, NY, USA: 2014. https://accesspharmacy.mhmedical.com/content.aspx?bookid=2222§ionid=172657843

19. Cahir E, Pillidge K, Drago J, Lawrence A. J. The necessity of a4* nicotinic receptors in nicotine-driven behaviors: dissociation between reinforcing and motor effects of nicotine. Neuropsychopharmacology. 2011;36(7):1505-17. doi:10.1038/npp.2011.35.

20. Rostron BL, Schroeder MJ, Ambrose BK. Dependence symptoms and cessation intentions among US adult daily cigarette, cigar, and e-cigarette users, 2012-2013. BMC Public Health. 2016 Aug 18;16(1):814. doi:10.1186/s12889-016-3510-2.

21. Nilan K, McNeill A, Murray RL, et al. survey of tobacco dependence treatment guidelines content in 61 countries. Addiction 2018 Feb 28. doi:10.1111/add.14204.

22. Titova ON, Sukhovskaya OA, Kozyrev AG, et al. Experience in providing medical care for quitting smoking to patients with respiratory diseases. Akademicheskij zhurnal Zapadnoj Sibiri. 2015;11(3(58)):35-8. (In Russ.)

23. Kozyrev AG, Sukhovskaya OA. Evaluation of smoking status in patients with bronchial asthma. Bolezni organov dyhaniya. 2009;(1): 18-21. (In Russ.)

24. Snaterse M, Scholte Op Reimer WJ, Dobber J, et al. Smoking cessation after an acute coronary syndrome: immediate quitters are successful quitters. Neth Heart J. 2015 Dec;23(12):600-7. doi:10.1007/s12471-015-0755-9.

25. Moore LC, Clark PC, Lee SY, et al. Smoking cessation in women at the time of an invasive cardiovascular procedure and 3 months later. J Cardiovasc Nurs. 2013 Nov-Dec;28(6):524-33.

26. Vogiatzis I, Pantzartzidou A, Pittas S, Papavasiliou E. Smoking Cessation Advisory Intervention in Patients with Cardiovascular Disease. Medical Archives. 2017;71(2):128-31. doi:10.5455/medarh.2017.71.128-131.

27. Gupta R, Gupta N, Khedar RS. Smokeless tobacco and cardiovascular disease in low and middle income countries. Indian Heart J. 2013 Jul-Aug;65(4):369-77.

28. Titova ON, Zasuhina TN, Kulikov VD, et al. Organization of assistance in quitting smoking in St. Petersburg: problems and solutions. Medicinskij al'yans. 2016;2:71-5. (In Russ.)

29. Kuz'micheva NA, Cygina TYu, Makarova NI. Features of treatment of tobacco dependence in a 72-year-old patient in a phthisio-pulmonary sanatorium. Medicinskij al'yans. 2016;3:69-72. (In Russ.)

30. Kutumova OYu, Kononova LI. Experience of Krasnoyarsk region in combating tobacco consumption and ensuring the implementation of Federal law No. 15-FZ. Medicinskij al'yans. 2016;(4):6-10. (In Russ.)

31. Yablonskiy PK, Sukhovskaya OA. Topical questions about healthy lifestyles (based on surveys of Russian citizens on the hotline for a healthy lifestyle). Medicinskij al'yans 2018;(4):92-8. (In Russ.)

32. Kulikov VD, Titova ON, Sukhovskaya OA, Kolpinskaya ND. Features of medical and psychological status with a high degree of nicotine addiction. Medicinskij al'yans. 2017;3:11-6. (In Russ.)

33. Kulikov VD, Titova ON. On the conceptual basis of the treatment of tobacco dependence. Zdorov'e naseleniya i sreda obitaniya. 2015;6(267):7-12. (In Russ.)

34. Suissa K, Lariviere J, Eisenberg MJ, et al. Efficacy and Safety of Smoking Cessation Interventions in Patients With Cardiovascular Disease: A Network Meta-Analysis of Randomized Controlled Trials.Circ Cardiovasc Qual Outcomes 2017 Jan; 10(1). pii:e002458. doi:10.1161/circoutcomes.115.002458.

35. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013 May 31;(5):CD009329. doi:10.1002/14651858.CD009329.pub2.

36. Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010 Jan 19;121(2):221-9. doi:10.1161/circulationaha.109.869008.

37. Eisenberg MJ, Windle SB, Roy N, et al. EVITA Investigators. Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome. Circulation. 2016 Jan 5;133(1):21-30. doi:10.1161/circulationaha.115.019634.

38. Windle SB, Dehghani P, Roy N, et al. EVITA Investigators. Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital. CMAJ. 2018 Mar 26;190(12):E347-E354. doi:10.1503/cmaj.170377.

39. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016 Jun 18;387(10037):2507-20. doi:10.1016/S0140-6736(16)30272-0.

40. Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012 May 4;344:e2856 doi:10.1136/bmj.e2856.

41. Benowitz N L, Pipe A, West R, et al. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial. JAMA Intern Med. 2018 May 1;178(5):622-31. doi:10.1001/jamainternmed.2018.0397.

42. Dollerup J, Vestbo J, Murray-Thomas T, et al. Cardiovascular risks in smokers treated with nicotine replacement therapy: a historical cohort study. Clin Epidemiol. 2017 Apr 26;9:231-43. doi:10.2147/clep.s127775.

43. Sukhovskaya OA, Smirnova MA, Kuznecova DN, Kulikov VD. Medico-social and psychological factors associated with the success of quitting smoking. Profilakticheskaya medicina. 2015;18,3:12-6. (In Russ.)

44. Chehab OM, Dakik HA. Interventions for smoking cessation in patients admitted with Acute Coronary Syndrome: a review. Postgrad Med J. 2018 Feb;94(1108):116-20. doi:10.1136/postgradmedj-2017-135040.

45. Ruger JP, Lazar CM. Economic evaluation of pharmaco- and behavioral therapies for smoking cessation: a critical and systematic review of empirical research. Annu Rev Public Health. 2012; 33:279-305.

46. Heidenreich PA, Zhao X, Hernandez AF, et al. Patient and hospital characteristics associated with traditional measures of inpatient quality of care for patients with heart failure. Am Heart J. 2012 Feb;163(2):239-45.

47. Bolman C, de Vries H, van Breukelen G. A minimal-contact intervention for cardiac inpatients: long-term effects on smoking cessation. Prev Med. 2002 Aug;35(2):181-92.

48. Koegelenberg CF, Noor F, Bateman ED, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. JAMA 2014 Jul; 312(2):155-61.


Review

For citations:


Sukhovskaya O.A., Kulikov N.V. Smoke cessation in cardiovascular pathology from the perspective of evidence-based medicine. Russian Journal of Cardiology. 2019;(2):86-91. (In Russ.) https://doi.org/10.15829/1560-4071-2019-2-86-91

Views: 1354


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)